Ribavirin and Interferon Therapy in Patients Infected with the Middle East Respiratory Syndrome Coronavirus An Observational Study
Al-Tawfiq, J.A., Momattin, H., Dib, J., and Memish, Z.A. (2014). Ribavirin and Interferon Therapy in Patients Infected with the Middle East Respiratory Syndrome Coronavirus: An Observational Study. International Journal of Infectious Diseases. 20:42-6.
The authors reviewed the therapeutic schedule and outcomes for five MERS patients who received ribavirin and interferon combination therapy an average of 19 days post-admission. None of the patients responded to therapy and all died, suggesting that this therapy is ineffective in patients with co-morbidities who start treatment late in the course of their illness.